Stoke Therapeutics, Inc. (STOK) financials: revenue, earnings and cash flow
Fiscal 2018–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Net income in fiscal 2025 was -$7M, a net margin of -3.7%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $28M and net income -$243M.
Free cash flow was $45M in fiscal 2025 and positive in 1 of the 8 years shown.
The diluted share count rose 8249% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $28M | $184M | $37M | $9M | $12M | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Operating income | -$258M | -$21M | -$101M | -$115M | -$104M | -$86M | -$53M | -$36M | -$13M |
| Net income | -$243M | -$7M | -$89M | -$105M | -$101M | -$86M | -$52M | -$32M | -$13M |
| EPS (diluted) | $-3.77 | $-0.12 | $-1.65 | $-2.38 | $-2.60 | $-2.34 | $-1.56 | $-1.80 | $-17.65 |
| R&D | $191M | $138M | $89M | $82M | $78M | $54M | $32M | $24M | $8M |
| Revenue growth | — | +404.5% | +316.3% | −29.2% | — | — | — | — | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$210M | $46M | -$87M | -$81M | -$32M | -$67M | -$42M | -$31M | -$11M |
| Capital spending | -$5M | -$670000 | -$203000 | -$2M | -$4M | -$1M | -$1M | -$2M | -$935000 |
| Free cash flow | -$216M | $45M | -$87M | -$83M | -$36M | -$68M | -$43M | -$33M | -$12M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $40M | $32M | $27M | $25M | $23M | $16M | $6M | $2M | $240000 |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $285M | $217M | $201M | $230M | $220M | $287M | $222M | $105M |
| Debt | — | $4M | $5M | $7M | $5M | $7M | $1M | $0 | $0 |
| Equity | — | $352M | $229M | $160M | $185M | $218M | $286M | $224M | $105M |
| Total assets | — | $418M | $272M | $228M | $256M | $239M | $298M | $229M | $108M |
| Shares (diluted) | 68M | 59M | 54M | 44M | 39M | 37M | 33M | 18M | 1M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | — |
| Operating margin | -913.1% | -11.2% | -277.3% | -1307.2% | -841.2% | — | — | — | — |
| Net margin | -862.1% | -3.7% | -243.4% | -1192.5% | -814.7% | — | — | — | — |
| FCF margin | -764.7% | 24.3% | -238.2% | -941.7% | -288.8% | — | — | — | — |
| ROIC | — | -4.6% | -34.2% | -54.5% | -43.4% | -30.2% | -14.6% | -12.6% | -9.6% |
| ROE | — | -1.9% | -38.9% | -65.6% | -54.7% | -39.4% | -18.3% | -14.4% | -11.9% |
Frequently asked questions
What is Stoke Therapeutics’s annual revenue?
$184M in fiscal 2025 and $28M over the twelve months to September 30, 2026.
How much profit does Stoke Therapeutics make?
Net income was -$7M in fiscal 2025 (net margin -3.7%).
Is Stoke Therapeutics’s revenue growing?
Yes: revenue rose 404.5% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.